<DOC>
	<DOCNO>NCT00251225</DOCNO>
	<brief_summary>The purpose study determine effectiveness two drug , docetaxel Gleevec® ( also call imatinib ) , prostate cancer longer respond hormone therapy . The investigator interest find combination two drug effective docetaxel alone treatment prostate cancer .</brief_summary>
	<brief_title>A Study Imatinib Docetaxel Prostate Cancer</brief_title>
	<detailed_description>This non-randomized multicenter Phase II trial Gleevec docetaxel chemo naïve metastatic hormone refractory prostate cancer . The primary objective study assess time disease progression patient hormone refractory prostate cancer treat daily oral imatinib intravenous docetaxel , administer every three week . Secondary objective include : 1 ) ass rate response imatinib docetaxel , use Prostate Specific Antigen ( PSA ) and/or measurable disease ; 2 ) ass overall survival patient hormone refractory prostate cancer treat imatinib docetaxel ; 3 ) evaluate qualitative quantitative toxicity combination .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Must histologic diagnosis adenocarcinoma prostate Stage D2 unresponsive refractory hormone therapy . Must metastatic prostate cancer rise PSA , deem hormone refractory . 2 . All subject must prestudy PSA within 28 day prior registration 3 . Subjects measurable disease must Xrays , scan physical examination use tumor measurement complete within 28 day prior registration . Subjects must nonmeasurable disease assess within 28 day ( PSA level ) 42 day ( image study ) prior registration . 4 . Subjects bone metastasis , document Xray , bone scan , MRI , biopsy . 5 . All subject must CT scan abdomen pelvis within 28 day prior registration . 6 . Subjects must surgically medically castrate . If method castration LHRH ( Luteinizing HormoneReleasing Hormone ) agonists , subject must willing continue use LHRH agonist . 7 . If subject treat nonsteroidal antiandrogens hormonal treatment agent must stop least 28 day prior enrollment flutamide ketoconazole , least 42 day prior enrollment bicalutamide nilutamide ; subject must demonstrate progression disease since agent suspend . 8 . Prior radiation therapy allow . At least 21 day must elapse since completion radiation therapy , subject must recover side effect radiation 9 . 9 . Due unknown side effect imatinib , men reproductive potential must agree use effective contraceptive method . 10 . Subjects must recover major infection and/or surgical procedure , opinion investigator , significant active concurrent medical illness preclude protocol treatment . 11 . ECOG performance status 01 12 . ANC ≥ 1,500/mL platelet count ³ 100,000/mL . These test must obtain within 7 day prior registration . 13 . Serum bilirubin ≤ 1.3 , SGOT SGPT ≤ 2 x institutional upper limit normal , serum creatinine ≤ 1.8 mg/dl . These test must obtain within 7 day prior registration . Testosterone level may do 28 day prior study entry . Testosterone level 50 ng/dL . 1 . No prior chemotherapy hormonerefractory disease allow . At least three week must elapse since completion noncytotoxic investigational therapy , patient must recover side effect therapy . 2 . No cytotoxics , biological response modifier , radiation therapy , corticosteroid hormonal concomitant therapy ( continue LHRH treatment ) may give protocol treatment . Bisphosphonates may give protocol treatment . No unconventional therapy may give protocol treatment . 3 . Subjects must NOT Grade III/IV cardiac problem define New York Heart Association Criteria . 4 . Subjects know chronic liver disease NOT eligible 5 . Must NOT know diagnosis human immunodeficiency virus ( HIV ) infection . 6 . Subjects must NOT know brain metastasis . 7 . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ carcinoma site , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>prostate</keyword>
</DOC>